NaMuscla Archives | Be Korea-savvy

Lupin Signs Distribution Agreements in Key EU Territories for Orphan Drug NaMuscla®

Zug, Switzerland, June 3 (Korea Bizwire) - Lupin is pleased to announce that it has entered into distribution agreements with three companies for its orphan drug NaMuscla® (mexiletine). Exeltis Healthcare S.L, Cresco Pharma B.V and Macure Pharma ApS will commercialize NaMuscula® for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in certain [...]

Lupin Neurosciences Announces Positive CHMP Opinion for NaMuscla™ for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

ZUG, Switzerland, Oct. 19 (Korea Bizwire) - Lupin Neurosciences, a specialty pharma division of Lupin Ltd, today announces that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the marketing authorization of NaMuscla™ (mexiletine hydrochloride) for the symptomatic treatment of myotonia [...]